An interventional study of Exercise in Amyloidosis, Hereditary, Transthyretin-Related, sponsored by University of Maia. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.
Sponsored by University of Maia · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal — 7 open to participants now, 9 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · Portugal.
Among the 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is the only one with no phase, and was the 14th registered.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →7 of the 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal are open now. Recruiting first, the newest first:
Bayer · Sites in Portugal, Austria, Belgium and 14 more countries
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in Portugal, United States, Argentina and 21 more countries
Ages 18–75
Intellia Therapeutics · Sites in Portugal, United States, Argentina and 23 more countries
Ages 18–90
Alnylam Pharmaceuticals · Sites in Portugal, United States, Brazil and 9 more countries
Universidade do Porto · Sites in Portugal
Ages 60+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 42 is below the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Median enrollment 474 across the 10 interventional studies, 1,500 across the 5 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 8 most frequent:
University of Maia is the lead sponsor of 21 studies on the registry; 13 are open to participants now.
University of Maia has 1 study filed under Amyloidosis, Hereditary, Transthyretin-Related — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to explore the effects of a 12-week exercise intervention on the physical and mental health of people living with Hereditary ATTR (ATTRv) Amyloidosis, a rare genetic disease caused by mutations in the transthyretin gene, leading to the deposition of amyloid fibrils in nerves and organs.
Considering that few studies to date have explored the effects of exercise in ATTRv Amyloidosis, this study aims to increase the existing evidence in this under-researched area. Besides, the existing research was performed with liver transplanted patients and focused exclusively on physical fitness outcomes. Therefore, we aim to include those patients who are currently receiving new therapies and extend research to the mental benefits of exercising, questioning whether exercise can ease the mental burden of living with such a debilitating disease. This research also seeks to raise awareness among patients and healthcare professionals about the importance of an active lifestyle in improving HRQoL in this community.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Having undergone a liver transplant in the past 6 months.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be enrolled in a 12-week supervised exercise intervention.
Other: Exercise
Participants will not be enrolled in the 12-week exercise program.
The exercise sessions will have a frequency of 3 times a week and a duration of 60 minutes per session. Exercise intensity will be gradually increased throughout the program and will be monitored every session using Borg's Rated Perceived Exertion scale, aiming at levels of 12-13 ("fairly light to somewhat hard"). The program will be mainly composed of cardiorespiratory exercises and resistance exercises. It will also comprise flexibility exercises to improve joint range of motion and neuromotor exercises involving motor skills (balance, agility, coordination, gait...), proprioceptive training and multifaceted activities (tai ji, yoga...).
Strength of the knee extensors
The strength of the knee extensors (N) will be assessed with a handheld strength device (DynaMo, VALD Performance).
Time frame: Strength of the knee extensors will be assessed at baseline and immediately after the 12-week exercise intervention.
Grip strength
Grip strength (N) will be assessed with a handheld strength device (DynaMo, VALD Performance).
Time frame: Grip strength will be assessed at baseline and immediately after the 12-week exercise intervention.
Walking capacity
Walking capacity will be assessed with the 6-minute walk test, registering the total distance covered in the test (m).
Time frame: Walking capacity will be assessed at baseline and immediately after the 12-week exercise intervention.
Body mass index
Body mass index (kg/m\^2) will be calculated from the ratio between weight and the square of height.
Time frame: Body mass index will be assessed at baseline and immediately after the 12-week exercise intervention.
Weight
Weight (kg) will be assessed with a bioelectrical impedance device (TANITA BC-545N).
Time frame: Weight will be assessed at baseline and immediatly after the 12-week exercise intervention.
Fat free mass
Fat free mass (kg) will be assessed with a bioelectrical impedance device (TANITA BC-545N).
Time frame: Fat free mass will be assessed at baseline and immediately after the 12-week exercise intervention.
Fat mass
Fat mass (%) will be assessed with a bioelectrical impedance device (TANITA BC-545N).
Time frame: Fat mass will be assessed at baseline and immediately after the 12-week exercise intervention.
Body water
Body water (kg) will be assessed with a bioelectrical impedance device (TANITA BC-545N).
Time frame: Body water will be assessed at baseline and immediately after the 12-week exercise intervention.
Mental health
Mental health will be evaluated using the Portuguese adaptation of the Mental Health Continuum-Short Form (MHC-SF), a mental-health questionnaire with 14 items that investigates respondent's emotional (3 items), social (5 items) and psychological (6 items) well-being. Each item is rated on a 6-point Likert scale, ranging from 0 (never) to 5 (everyday).
Time frame: Mental health will be assessed at baseline and immediately after the 12-week exercise intervention.
Health-related quality of life (HRQoL)
To assess HRQoL, the EQ-5D-3L will be used to determine patients' health state in 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2) and extreme problems (3).
Time frame: HRQoL will be assessed at baseline and immediately after the 12-week exercise intervention.
Plan to share: No — The study will involve the collection of sensitive personal data regarding patient's physical and mental health.
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Sep 2025, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloidosis, Hereditary, Transthyretin-Related →
University of Maia